Healthcare

Berkshire’s move comes as Japan’s Nikkei stock index records gains of more than 10% over the past three months.

Mizuho Securities USA analyst Steven Valiquette initiated coverage of the company with an Outperform rating and $36 price target.

HHS Secretary Robert F. Kennedy Jr. says the shot will be available for people aged 5 and older.

AT&T intends to buy spectrum licenses from EchoStar for $23 billion, while shares of Advanced Micro Devices receive an upgrade.

As tech stocks float at historic highs, it’s a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.

Tech, consumer and industrial companies, and utilities have powered the index higher. They could keep gaining for a while.

The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.

For investors worried about elevated market valuations, they may be just what the doctor ordered.

The Covid-19 pandemic is over, but the virus persists

T. Rowe Price’s David Giroux is a top-performing manager whose fund is closed to new investors. But now he’s running three other funds. See how they measure up.

Medtronic appoints two new board directors following talks with activist investor Elliott Investment Management.

Analysts’ price forecasts are a hint that gains for stocks may broaden out beyond the usual suspects in big tech.

Warren Buffett’s company disclosed it bought 5 million shares during the second quarter.

Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer blockbuster.

Dayforce soars following a report that says it could be bought by private-equity firm Thoma Bravo.

GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.

Even though Warren Buffett seems to think the value of UnitedHealth stock is about right, that doesn’t mean investors should ignore the long list of unresolved issues facing the company.

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

Trump’s Putin meeting crucial for oil prices, Berkshire Hathaway’s mystery solved, the case for rate cuts, and more news to start your day.

The weighting for tech in the S&P 500 continues to grow, even as tech capital spending for AI explodes. Energy and healthcare have been beaten down, but it looks as if their time is coming.

Health insurers are requesting the largest monthly premium increases in more than five years

Warren Buffett disclosed the moves in a securities filing on Thursday.

The U.K. list price for the largest dose version of Mounjaro is going up 170%.

Analysts at Baird Equity Research upgraded the stock to Outperform from Neutral.

Other company insiders purchased stock too, including Lilly’s executive vice president.